|Bid||0.00 x 900|
|Ask||0.00 x 1000|
|Day's range||6.05 - 6.29|
|52-week range||5.42 - 20.60|
|Beta (5Y monthly)||0.50|
|PE ratio (TTM)||N/A|
|Earnings date||22 Feb 2023 - 27 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||24.85|
Post FDA's feedback on lifileucel, Iovance (IOVA) extends its timeline to complete the rolling BLA submission for lifileucel in melanoma. It expects to complete the filing in the first quarter.
The FDA is asking the drug development outfit for more information regarding its tumor-infiltrating lymphocyte therapy.
Iovance Biotherapeutics (IOVA) reports a wider-than-expected loss in Q3. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.